The blood system is quietly central to how we age. Hematopoietic stem cells (HSCs) orchestrate lifelong immune competence, red blood cell turnover, and clot formation — yet their progressive dysfunction with age contributes to immunosenescence, anemia, and elevated cancer risk through clonal hematopoiesis. A clearer mechanistic map of why these cells fail could reframe how clinicians and researchers approach systemic aging itself.
This comprehensive review in Genome Biology synthesizes the full life-arc of HSCs — from fetal expansion through adult homeostasis to age-related decline — cataloguing the hallmarks of aging HSCs: a paradoxical increase in phenotypic HSC numbers despite reduced functional self-renewal capacity, diminished long-term reconstitution ability, a pronounced myeloid differentiation bias, and the accumulation of clonal hematopoiesis. The authors integrate both cell-intrinsic drivers — including epigenetic drift, DNA damage accumulation, mitochondrial dysfunction, and altered metabolic states — with cell-extrinsic factors such as niche remodeling and systemic inflammatory signals (inflammaging). Crucially, the review highlights emerging rejuvenation strategies targeting these axes, including epigenetic reprogramming, niche manipulation, and metabolic interventions.
This synthesis arrives at a meaningful inflection point in aging biology. Clonal hematopoiesis of indeterminate potential (CHIP), now recognized as an independent cardiovascular and oncologic risk factor affecting roughly 10–20% of adults over 70, anchors HSC aging directly to measurable population-level disease burden. The myeloid bias described here mechanistically explains the age-related shift toward chronic inflammation over adaptive immunity. While the reviewed rejuvenation strategies remain largely preclinical — demonstrated in murine models or in vitro — several epigenetic and metabolic targets are actively entering early-phase human trials. The review's strength is its integrative framing, though readers should note that translating HSC rejuvenation from mouse to human has historically proven difficult due to species differences in HSC niche architecture and clonal dynamics. Overall, this represents a high-value synthesis for researchers and clinicians tracking the convergence of stem cell biology and longevity medicine.